Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Fusion protein of cytokine combined with chimeric antigen receptor and its application

A chimeric antigen receptor and fusion protein technology, applied in the field of biomedicine, can solve the problems of lack of safe and deliberate targets, complex tumor immune microenvironment, poor treatment effect, etc. Tumor effect, good anti-tumor effect

Active Publication Date: 2021-12-10
SUN YAT SEN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Based on the breakthrough of CAR T in the treatment of blood tumors, CAR T therapy has been further extended to the treatment of solid tumors, and has been explored in various solid tumors including breast cancer, liver cancer, colorectal cancer and lung cancer. Unlike hematological tumors, it lacks safe and specific targets, and solid tumors have a complex tumor immune microenvironment, which ultimately leads to poor therapeutic effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein of cytokine combined with chimeric antigen receptor and its application
  • Fusion protein of cytokine combined with chimeric antigen receptor and its application
  • Fusion protein of cytokine combined with chimeric antigen receptor and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0070] 1 Construction of T2-mCAR molecules co-expressing IL-7 and CCL3

[0071] The mouse CAR gene constructed based on the retroviral vector backbone can be efficiently transduced into mouse T cells. Based on the original mouse second-generation CAR molecule T2-m28z, we constructed a co-expression mouse protein IL -7 and CCL3 mCAR fusion protein. Mouse IL-7 and CCL3 proteins are connected to the 3' end of the CAR gene without a stop codon by using a cleavable fusion protein adapter sequence (2A peptide, P2A). Since P2A can cut itself independently of proteases, The two structural domains are broken to achieve the result of co-expression of the three molecules. So far, we have constructed the murine CAR structure of T2-m28z IL7CCL3 ( 7P3 ), its amino acid sequence is shown in SEQ ID NO: 12, and its structure is shown in figure 1 shown.

[0072] 2 Preparation of CAR T cells co-expressing IL-7 and CCL3

[0073] The present invention prepares mCAR T cells according to the ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biomedicine, in particular to a fusion protein of cytokine combined with chimeric antigen receptor and its application. The fusion protein includes chimeric antigen receptor, 2A peptide, IL-7, 2A peptide and CCL3 in series; the chimeric antigen receptor includes scFv region, hinge region, transmembrane domain and intracellular signal conduction region. The present invention adds two cytokines IL-7 and CCL-3 when constructing the CAR vector, and the two cytokines can enhance the anti-apoptotic effect of CAR T cells and reduce their immunosuppressive effect, thereby helping CAR T cells to enhance anti-tumor effect.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a fusion protein of cytokine combined with chimeric antigen receptor and its application. Background technique [0002] Malignant tumors have become one of the leading causes of death worldwide. With the continuous development of science and technology, through the early diagnosis and treatment of cancer, the cure rate of cancer has been greatly improved and the quality of life of patients has been improved. However, most malignant tumors still have problems such as poor prognosis and easy recurrence. Among all tumor treatments, immunotherapy has received constant attention and expectations from researchers. The biggest feature of immunotherapy is to use the immune system itself to fight cancer, including antibody therapy, cell therapy and immunomodulator therapy. Among them, cell therapy, which has attracted much attention, refers to the reinfusion of cell preparations into the pat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/85C12N5/10A61K39/00A61K38/20A61K38/19A61P35/00
CPCC07K14/5418C07K14/7051C07K14/523C12N5/0636C12N15/85A61K39/001111A61K38/2046A61K38/195A61P35/00C12N2510/02C07K2319/02C07K2319/03A61K2039/5158A61K2300/00
Inventor 黄朝峰陈焕鹏
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com